Antipodes Partners LTD Natera, Inc. Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Natera, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 313 shares of NTRA stock, worth $52,380. This represents 0.0% of its overall portfolio holdings.
Number of Shares
313
Previous 283
10.6%
Holding current value
$52,380
Previous $40,000
30.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NTRA
# of Institutions
707Shares Held
125MCall Options Held
590KPut Options Held
260K-
Vanguard Group Inc Valley Forge, PA12.7MShares$2.12 Billion0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.2MShares$2.04 Billion0.23% of portfolio
-
Jpmorgan Chase & CO New York, NY7.36MShares$1.23 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY6.77MShares$1.13 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.82MShares$807 Million3.66% of portfolio
About Natera, Inc.
- Ticker NTRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 96,957,400
- Market Cap $16.2B
- Description
- Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...